作者: A. Miller , S. Nussbaum , E. Staun-Ram , A. Snir , L. Hayardeny Nisimov
DOI: 10.1212/WNL.78.1_MEETINGABSTRACTS.P02.116
关键词:
摘要: Objective: The goal of this study was to assess the immunomodulatory in vitro effects laquinimod on B cells from patients with relapsing-remitting multiple sclerosis (RRMS). Background benefit cell-depleting therapy and other lines evidence have emphasized a role MS. Laquinimod is novel orally administered drug under development for treatment MS, whose mode action not fully elucidated. Clinical data so far suggest that safe, well-tolerated efficacious reducing MRI measures disease activity, clinical relapses slowing progression disability. Design/Methods: naive MS were cultured or without 1uM 24hrs, analyzed by FACS known cell markers. CD4+ T RRMS co-cultured 72hrs, stimulation CD3/CD28 PMA+ionomycin, cytokine levels both cells, proliferation assessed FACS. Results: increased percentage CD86+ IL10+ within CD25+ subset, all markers associated regulatory functions. demonstrated their capacity IFNg+ cells. Laquinimod-treated reduced expression IFNg IL4 IL10 TGFb B-cell mediated manner. also IL4, induced co-culture, decreased alone. Conclusions: modulates characteristics functions, affecting cell-mediated- profile, which may be part beneficial patients. Supported by: Financial support Teva Pharmaceuticals. Disclosure: Dr. Miller has received personal compensation activities Pharmaceutical Industries Ltd., Medison Pharma Biogen Idec, Merck Serono, Avanir Pharmaceuticals, Novartis, Bayer Schering Pharma. research Nussbaum nothing disclose. Staun-Ram Snir Hayardeny Nisimov Melamed Neuroscience. Toubi